glp-1 expression From metabolism to mind: The expanding role of the receptor in neurotherapeutics GLP-1 | Summary
Description
Evolution of GLP-1-based therapeutics First-generation GLP-1RAs The development of GLP-1 receptor agonists stemmed from the significant finding that natural GLP-1 had an exceptionally short half-life of about 1.5 to 5 min, due to its rapid degradation by the enzyme DPP-4 (Campbell and Drucker 2013) (Fig
North America leads due to strong R&D capacity, presence of major pharmaceutical players, and supportive regulatory frameworks
Do not freeze them
You finally took the plunge and started taking a GLP-1 drug to improve your health
In summary, convergent evidence from both preclinical and clinical research underscores the capacity of GLP-1RAs to interact with neural circuits that govern reinforcement and motivation, networks that are also targeted by drugs of abuse
However, the study included a small number of participants and a shorter follow up time of only 48 weeks compared to other RCTs studying GLP-1 agonists
